Creagene to conduct phase 1 study of novel rheumatoid arthritis treatment

Creagene, a subsidiary of Choong-wae Pharm, said on June 11 that it will conduct Creavax-RA injection, a rheumatoid arthritis treatment using immunoregulation dendritic cells sooner or later after its approval from the Korea Food and Drug Administration.

A spokesman at Creagene stated “Creagene researchers, by observing rheumatoid arthritis to be an autoimmune disease occurring due to abnorm...